Furthermore, CaMKK2 expression is markedly increased in a carcinogen-induced HCC mouse model and pharmacological inhibition of CaMKK2 with STO-609 regresses hepatic tumor burden. This evidence concerns the gene CAMKK2 and hepatocellular carcinoma.